Headlines about AngioDynamics (NASDAQ:ANGO) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.7585573867875 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- AngioDynamics, Inc. (ANGO) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : December 15, 2017 (finance.yahoo.com)
- AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018 (finance.yahoo.com)
- $0.17 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter (americanbankingnews.com)
AngioDynamics (NASDAQ:ANGO) traded up $0.26 during midday trading on Monday, reaching $17.25. The company had a trading volume of 601,100 shares, compared to its average volume of 235,050. The company has a market capitalization of $633.35, a P/E ratio of 25.00, a PEG ratio of 1.77 and a beta of 1.04. The company has a quick ratio of 1.48, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. AngioDynamics has a fifty-two week low of $14.80 and a fifty-two week high of $18.85.
ANGO has been the subject of a number of recent research reports. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research report on Friday, August 25th. Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Tuesday, October 3rd. Finally, Canaccord Genuity restated a “hold” rating and set a $17.00 target price on shares of AngioDynamics in a research report on Sunday, October 8th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.60.
TRADEMARK VIOLATION NOTICE: “AngioDynamics (ANGO) Receiving Somewhat Positive Media Coverage, Analysis Shows” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/12/18/angiodynamics-ango-receiving-somewhat-positive-media-coverage-analysis-shows.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.